News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Johns Hopkins Research Team Uses Machine Learning on DNA “Dark Matter” in Blood to Identify Cancer

Findings could lead to new biomarkers clinical laboratories would use for identifying cancer in patients and monitoring treatments

As DNA “dark matter” (the DNA sequences between genes) continues to be studied, researchers are learning that so-called “junk DNA” (non-functional DNA) may influence multiple health conditions and diseases including cancer. This will be of interest to pathologists and clinical laboratories engaged in cancer diagnosis and may lead to new non-invasive liquid biopsy methods for identifying cancer in blood draws.

Researchers at Johns Hopkins Kimmel Cancer Center in Baltimore, Md., developed a technique to identify changes in repeat elements of genetic code in cancerous tissue as well as in cell-free DNA (cf-DNA) that are shed in blood, according to a Johns Hopkins news release.

The Hopkins researchers described their machine learning approach—called ARTEMIS (Analysis of RepeaT EleMents in dISease)—in the journal Science Translational Medicine titled, “Genomewide Repeat Landscapes in Cancer and Cell-Free DNA.”

ARTEMIS “shows potential to predict cases of early-stage lung cancer or liver cancer in humans by detecting repetitive genetic sequences,” Genetic Engineering and Biotechnology News (GEN) reported.

This technique could enable non-invasive monitoring of cancer treatment and cancer diagnosis, Technology Networks noted.

“Our study shows that ARTEMIS can reveal genomewide repeat landscapes that reflect dramatic underlying changes in human cancers,” said study co-leader Akshaya Annapragada (above), an MD/PhD student at the Johns Hopkins University School of Medicine, in a news release. “By illuminating the so-called ‘dark genome,’ the work offers unique insights into the cancer genome and provides a proof-of-concept for the utility of genomewide repeat landscapes as tissue and blood-based biomarkers for cancer detection, characterization, and monitoring.” Clinical laboratories may soon have new biomarkers for the detection of cancer. (Photo copyright: Johns Hopkins University.)

Detecting Early Lung, Liver Cancer

Artemis is a Greek word meaning “hunting goddess.” For the Johns Hopkins researchers, ARTEMIS also describes a technique “to analyze junk DNA found in tumors” and which float in the bloodstream, Financial Times explained.

“It’s like a grand unveiling of what’s behind the curtain,” said geneticist Victor Velculescu, MD, PhD, Professor of Oncology and co-director of the Cancer Genetics and Epigenetics Program at Johns Hopkins Kimmel Cancer Center, in the news release.

“Until ARTEMIS, this dark matter of the genome was essentially ignored, but now we’re seeing that these repeats are not occurring randomly,” he added. “They end up being clustered around genes that are altered in cancer in a variety of different ways, providing the first glimpse that these sequences may be key to tumor development.”

ARTEMIS could “lead to new therapies, new diagnostics, and new screening approaches for cancer,” Velculescu noted.

Repeats of DNA Sequences Tough to Study

For some time technical limitations have hindered analysis of repetitive genomic sequences by scientists. 

“Genetic changes in repetitive sequences are a hallmark of cancer and other diseases, but characterizing these has been challenging using standard sequencing approaches,” the study authors wrote in their Science Translational Medicine paper.

“We developed a de novo k-mer (short sequences of DNA)-finding approach called ARTEMIS to identify repeat elements from whole-genome sequencing,” the researchers wrote.

The scientists put ARTEMIS to the test in laboratory experiments.

The first analysis involved 1,280 types of repeating genetic elements “in both normal and tumor tissues from 525 cancer patients” who participated in the Pan-Cancer Analysis of Whole Genomes (PCAWG), according to Technology Networks, which noted these findings:

  • A median of 807 altered elements were found in each tumor.
  • About two-thirds (820) had not “previously been found altered in human cancer.”

Second, the researchers explored “genomewide repeat element changes that were predictive of cancer,” by using machine learning to give each sample an ARTEMIS score, according to the Johns Hopkins news release. 

The scoring detected “525 PCAWG participants’ tumors from the healthy tissues with a high performance” overall Area Under the Curve (AUC) score of 0.96 (perfect score being 1.0) “across all cancer types analyzed,” the Johns Hopkins’ release states.

Liquid Biopsy Deployed

The scientists then used liquid biopsies to determine ARTEMIS’ ability to noninvasively diagnose cancer. Researchers used blood samples from:

Results, according to Johns Hopkins:

  • ARTEMIS classified patients with lung cancer with an AUC of 0.82.
  • ARTEMIS detected people with liver cancer, as compared to others with cirrhosis or viral hepatitis, with a score of AUC 0.87.

Finally, the scientists used their “ARTEMIS blood test” to find the origin of tumors in patients with cancer. They reported their technique was 78% accurate in discovering tumor tissue sources among 12 tumor types.

“These analyses reveal widespread changes in repeat landscapes of human cancers and provide an approach for their detection and characterization that could benefit early detection and disease monitoring of patients with cancer,” the researchers wrote in Science Translational Medicine.

Large Clinical Trials Planned

Velculescu said more research is planned, including larger clinical trials.

“While still at an early stage, this research demonstrates how some cancers could be diagnosed earlier by detecting tumor-specific changes in cells collected from blood samples,” Hattie Brooks, PhD, Research Information Manager, Cancer Research UK (CRUK), told Financial Times.

Should ARTEMIS prove to be a viable, non-invasive blood test for cancer, it could provide pathologists and clinical laboratories with new biomarkers and the opportunity to work with oncologists to promptly diagnosis cancer and monitor patients’ response to treatment.

—Donna Marie Pocius

Related Information:

“Junk DNA” No More: Johns Hopkins Investigators Develop Method of Identifying Cancers from Repeat Elements of Genetic Code

Genomewide Repeat Landscapes in Cancer and Cell-Free DNA

AI Detects Cancer VIA DNA Repeats in Liquid Biopsies

Genetic “Dark Matter” Could Help Monitor Cancer

AI Explores “Dark Genome” to Shed Light on Cancer Growth

Might Bacteria be Used to Identify Cancer Cells? Some Researchers Using Synthetic Biology and Genetic Engineering Techniques Say ‘Yes’

Cellular healthcare is an approach that goes beyond clinical laboratory testing to identify the location of specific cancer cells and aid in treatment decisions

Advances in synthetic biology and genetic engineering are leading to development of bacterial biosensors that could eventually aid pathologists and clinical laboratories in diagnosis of many types of cancers.

One recent example comes from researchers at the University of California San Diego (UCSD) who worked with colleagues in Australia to engineer bacteria that work as “capture agents” and bind to tumorous material.

The resulting “bacterial biosensors” go on a “sort of molecular manhunt” to find and capture tumor DNA with mutations in the Kirsten Rat Sarcoma virus (KRAS) gene, according to an article published by the National Cancer Institute (NCI) titled, “Could Bacteria Help Find Cancer?

The KRAS gene is associated with colorectal cancer. The researchers named their development the Cellular Assay for Targeted CRISPR-discriminated Horizontal gene transfer (CATCH). 

CATCH successfully detected cancer in the colons of mice. The researchers believe it could be used to diagnose cancers, as well as infections and other diseases, in humans as well, according to a UCSD news release.

The researchers published their proof-of-concept findings in the journal Science titled, “Engineered Bacteria Detect Tumor DNA.”

Daniel Worthley, PhD

“If bacteria can take up DNA, and cancer is defined genetically by a change in its DNA, then, theoretically, bacteria could be engineered to detect cancer,” gastroenterologist Daniel Worthley, PhD, a cancer researcher at Colonoscopy Clinic in Brisbane, Australia, told MedicalResearch.com. This research could eventually provide clinical laboratories and anatomic pathologists with new tools to use in diagnosing certain types of cancer. (Photo copyright: Colonoscopy Clinic.)

Tapping Bacteria’s Natural Competence

In their Science paper, the researchers acknowledged other synthetic biology achievements in cellular biosensors aimed at human disease. But they noted that more can be done by leveraging the “natural competence” skill of bacteria. 

“Biosensors have not yet been engineered to detect specific extracellular DNA sequences and mutations. Here, we engineered naturally competent Acinetobacter baylyi (A. baylyi) to detect donor DNA from the genomes of colorectal cancer cells, organoids, and tumors,” they wrote.

“Many bacteria can take up DNA from their environment, a skill known as natural competence,” said Rob Cooper, PhD, co-first author of the study and a scientist at US San Diego’s Synthetic Biology Institute, in the news release. A. baylyi is a type of bacteria renowned for success in doing just that, the NCI article pointed out. 

CRISPR Aids CATCH Development

Inside Precision Medicine shared these steps toward creation of the CATCH technique:

  • Researchers engineered bacteria using CRISPR.
  • This enabled them to explore “free-floating DNA sequences on a genomic level.”
  • Those sequences were compared to “known cancer DNA sequences.”
  • A. baylyi (genetically modified) was tested on its ability to detect “mutated and healthy KRAS DNA.”
  • Only bacteria that had “taken up mutated copies of KRAS … would survive treatment with a specific drug.”

“It was incredible when I saw the bacteria that had taken up the tumor DNA under the microscope. The mice with tumors grew green bacterial colonies that had acquired the ability to be grown on antibiotic plates,” said Josephine Wright, PhD, Senior Research Fellow, Gut Cancer Group, South Australian Health and Medical Research Institute (SAHMRI), in the news release. 

Detecting DNA from Cancer Cells In Vitro and in Mice

Findings in vitro and in mice include the following:

  • The engineered bacteria enabled detection of DNA with KRAS G12D from colorectal cancer cells made in the lab, NCI reported.
  • When mice were injected with colorectal cancer cells, the researchers’ technology found tumor DNA, Engadget reported.

The study adds to existing knowledge of horizontal gene transfer from bacteria to bacteria, according to UCSD.

“We observed horizontal gene transfer from the tumor to the sensor bacteria in our mouse model of colorectal cancer. This cellular assay for targeted, CRISPR-discriminated horizontal gene transfer (CATCH) enables the biodetection of specific cell-free DNA,” the authors wrote in Science.

“Colorectal cancer seemed a logical proof of concept as the colorectal lumen is full of microbes and, in the setting of cancer, full of tumor DNA,” gastroenterologist Daniel Worthley, PhD, a cancer researcher at Colonoscopy Clinic in Brisbane, Australia, told MedicalResearch.com.

Finding More Cancers and Treatment

More research is needed before CATCH is used in clinical settings. The scientists are reportedly planning on adapting CATCH to multiple bacteria that can locate other cancers and infections.

“The most exciting aspect of cellular healthcare … is not in the mere detection of disease. A laboratory can do that,” wrote Worthley in The Conversation. “But what a laboratory cannot do is pair the detection of disease (a diagnosis) with the cells actually responding to the disease [and] with appropriate treatment.

“This means biosensors can be programmed so that a disease signal—in this case, a specific sequence of cell-free DNA—could trigger a specific biological therapy, directly at the spot where the disease is detected in real time,” he added.

Clinical laboratory scientists, pathologists, and microbiologists may want to stay abreast of how the team adapts CATCH, and how bacterial biosensors in general continue to develop to aid diagnosis of diseases and improve ways to target treatment.

—Donna Marie Pocius

Related Information:

Could Bacteria Help Find Cancer?

Researchers Engineer Bacteria That Can Detect Tumor DNA

Engineered Bacteria Can Act as Biosensors to Detect Cancer DNA

Engineered Bacteria Detect Tumor DNA

Engineered Bacteria Can Detect Tumor DNA

Scientists Genetically Engineer Bacteria to Detect Cancer Cells

Genetically Engineered Bacteria Can Detect Cancer Cells in a World-First Experiment

Protein Catalyzed Capture Agents

;